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Randomized controlled trials (RCTs) with appropriate 
question selection, careful subject enrollment, adequate 
powering and assiduous execution of a well-designed 
protocol can provide convincing data that improve the 
strength of the evidence base guiding practice. How-
ever, many RCTs conducted in intensive care medicine 
have resulted in no significant differences in primary 
outcomes between the tested groups. This is particu-
larly true for trials targeting mortality. Because patients 
in RCTs in critical care medicine—and patients in inten-
sive care units (ICUs)—have wide variability in their risk 
of death, these patients will also have wide variability in 
the absolute benefit that they can derive from a given 
therapy. If the adverse effects of the therapy are not per-
fectly aligned with the treatment benefits, this will result 
in heterogeneity of the treatment effect, wherein differ-
ent patients experience quite different and often unex-
pected results from therapy. As a consequence, in a nega-
tive RCT, there are patients who experience benefit and 
others who experience harm, all merged into the global 
result. Therefore, the results do not provide a definitive 
answer to the study question or enable reliable guid-
ance or recommendations to be developed. Indeed, these 
negative clinical trials seldom convey useful information 
beyond that stemming from an examination of their sub-
groups, their possibly inopportune assumptions and their 
deficiencies of design.
Why are so many RCTs in critically ill patients nega-
tive? First, most studies use all-cause mortality as the 
targeted outcome, but the underlying cause of death, per-
haps especially in ICU patients, is highly variable and can 
be influenced by multiple elements, including comor-
bidities, treatment choices, personal preferences and 
other unaccounted factors that can blur the effects of the 
intervention. Moreover, the intervention may be effective 
but not influence the overall mortality of the group. Sur-
rogate or intermediate endpoints that are better indica-
tors of potential effect help to improve sensitivity. This 
has been shown to be true in studies on the management 
of acute respiratory failure [1] and optimal nutritional 
support.
Second, we should remember that the comparison 
between groups of an RCT tests whether any observed 
difference cannot be explained statistically by chance 
alone (rejects the null hypothesis). To achieve this pur-
pose, the patient population must be carefully selected, 
and there must be a clear rationale for a difference to be 
expected—an element that is often missed during trial 
design. The risk of type II error in RCTs is not the only 
issue. Indeed, in most negative trials, there was not even 
a suggestion of a positive outcome. Ability to indicate a 
difference between groups is more a matter of disease 
severity, especially when a reduction in mortality is the 
target [2]. These issues are well illustrated by two recent 
trials on the use of corticosteroids in septic shock. One 
(the ADRENAL study) reported no difference in mortal-
ity when the placebo group mortality rate was 29% [3], 
but the other (the APROCCHSS study) showed a signifi-
cant difference when the placebo group mortality rate 
was 49% [4]. The ADRENAL trial [3] enrolled patients 
at a rate approximately five times higher than other large 
trials in septic shock, but only about half the patients 
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were receiving significant doses of norepinephrine, and 
the mortality rate was less than 30%. Too many trials, 
under pressure to enroll a large number of patients over 
a short time period (Box  1), capture patients who meet 
the inclusion criteria but do not really represent the pop-
ulation most likely to benefit from the study interven-
tion. The negative results of a large RCT testing a precise 
question with clear and rational alternatives, appropriate 
patient selection, and thoughtful design and execution 
have clear potential to yield more informative results. 
Unfortunately, such criteria are seldom met in critical 
care.
Third, conditions such as sepsis or ARDS are not dis-
eases but syndromes, originating from a variety of 
causes and mechanisms. The rapidly advancing field of 
biomarker identification may eventually help in patient 
identification and selection, but we are not there yet. To 
improve outcomes in complex critically ill patients with 
these syndromes, the underlying causative disease must 
be taken into consideration. As an example, randomiza-
tion of patients with septic shock to a lower versus higher 
blood pressure target will almost certainly yield negative 
results [5], because some patients, e.g., those with athero-
sclerosis and arterial hypertension, may require a higher 
arterial blood pressure than their younger counterparts 
with fewer comorbidities. These negative results could 
be incorrectly interpreted as meaning that the blood 
pressure level is not important in septic shock and that 
all patients can be left with a mean arterial pressure of 
65 mmHg; clearly this is not appropriate.
It is important not to overinterpret the results of nega-
tive RCTs. After all, lack of proof of benefit does not 
imply proof of lack of benefit. Incorrect interpretation 
of a negative trial may have serious consequences for 
patient care and for the advancement of our field. This 
is also illustrated by RCTs supporting restrictive strate-
gies on blood transfusion in critically ill patients. The 
randomization of patients according to hemoglobin 
thresholds in those influential studies should be viewed 
as suboptimal, as it is clear that the decision to transfuse 
should not be based only on this information, but on 
other factors, including underlying coronary disease [6]. 
In these studies on transfusion, enrollment rates were 
quite low, largely because physicians preferred to trans-
fuse some patients who may have been study candidates 
but for whom they considered ethical or scientific equi-
poise was not present. Hence, these enrolled patients 
may actually not have needed a blood transfusion and 
were unlikely to benefit. Similarly, the negative trials on 
early goal-directed therapy in patients with sepsis could 
have been anticipated, with many patients requiring no 
aggressive intervention because they were either already 
resuscitated or only mildly ill [7]. With the lack of evi-
dence of an impact on patient outcome, some clinicians 
became skeptical about the need for central venous cath-
eters and some have moved away from cardiac output 
assessment.
Because negative trials carry serious and often unin-
tended consequences, there is a pressing need to address 
the major problems in design and execution before under-
taking them. For example, authorities and decision-mak-
ers may use the results of negative trials to justify avoiding 
the costs of sporadically useful but unproven interven-
tions. This is why the need to conduct RCTs for extracor-
poreal membrane oxygenation (ECMO) has generated so 
much controversy [8]; a negative clinical trial may hinder 
reimbursement of this potentially lifesaving procedure. 
From the viewpoint of industry, negative RCTs decrease 
enthusiasm to develop new medications for sepsis, and 
the idea that critical care is a very difficult area in which 
to perform clinical trials is becoming increasingly estab-
lished, limiting investment in this field of research.
In summary, a negative RCT in a heterogeneous, 
poorly defined population provides little if any new infor-
mation. It does not even tell us much about mechanisms. 
Separating heterogeneous patient populations into only 
two groups for the purposes of an RCT is a rather sim-
plistic approach. For individual patients, optimal dosing 
is crucial to effectiveness: applying a single PEEP level 
[9], the same amount of fluid, the same blood pressure 
value, the same transfusion trigger in all patients makes 
no sense. The main message of a negative trial in critically 
ill patients is that the decision process is more complex 
than one may think and treatment should be targeted to 
the needs of the individual, rather than to heterogeneous 
groups of patients. In a sense, it is reassuring that nega-
tive RCTs stress the complexity of critical care medicine 
and the need for careful reflection at the bedside. The 
nosography of critical illness is still in its infancy, and we 
need to include appropriate biomarkers in our evalua-
tions. We need to choose therapies according to the spe-
cific needs of individual patients and not offer the same 
treatments for all.
Box 1 Some perceived benefits that motivate clinicians 
to participate in large multicenter randomized controlled 
trials (RCTs)
Scientific (to address an important question)
Practical/pragmatic (benefit for patient care)
Financial (benefit for the department)
Political (benefit for the hospital/group)
Academic (for individual recognition/promotion)
Societal (benefit for society)
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